N/A N=146 Prevalence of Renal Artery Stenosis in Patients Referred for Cardiac Catheterization
Renal Artery Stenosis
Primary: Prevalence of Renal Artery Stenosis (RAS)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=68 Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension
Renal Artery Stenosis · Hypertension, Renovascular
Primary: Primary Patency — 66 Subject-lesions — p=<.0001
Phase 3 N=947 Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions
Atherosclerosis · Cardiovascular Diseases · Hypertension, Renovascular
Primary: Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent…
N/A N=100 REFORM Clinical Study: Treatment of Renal Artery Stenosis With the Formula Balloon-Expandable Stent
Renal Artery Stenosis
Primary: Primary Patency of the Treated Renal Artery — 91 Lesions — p=<0.0001
N/A N=47 Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Hypertension
Primary: Adverse Events — 47.8 percentage of participants
N/A N=202 The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis
Renal Artery Obstruction · Hypertension, Renal
Primary: Binary Restenosis Rate — 10.5 Percentage of lesions — p=< 0.0001
N/A N=33 RAAS and Arterial Stiffness in SCI
Arterial Stiffness · Renin Angiotensin Aldosterone System · Orthostatic Hypotension
Primary: Pulse Wave Velocity (m/s) — 8.81; 7.36; 5.53 m/s
N/A N=655 Aortoiliac Stenosis in Kidney Transplantation
Aorto-Iliac Arterial Stenosis · Peripheral Arterial Disease · Kidney Transplant Failure
Primary: Patient Survival — 322; 48; 6 Participants
N/A N=146 Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter
Hypertension
Primary: Change in Systolic and Diastolic Blood Pressure at Six (6) Months as Measured by Office-based Blood Pressure Assessment — -24.5; -10.3 mm Hg
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 1 N=19 RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157
Hypertension, Renal
Primary: Incidence of Major Adverse Events That Occurred Within 30 Days Post-procedure. — 0.0 percentage of participants
N/A N=55 Distal Renal Denervation
Hypertension, Resistant to Conventional Therapy
Primary: Changes of 24h-mean Systolic BP Assessed by Ambulatory Blood Pressure Monitoring (ABPM) — 21.1; 10.3 mmHg — p=0.045
N/A N=10 Measurement of Kidney Blood Flow and Oxygen Levels by MRI
Chronic Kidney Disease
Primary: Measurement of Renal Blood Flow of the Kidney by the PAH Method — 190 ml/min
N/A N=50 Rapid Renal Sympathetic Denervation for Resistant Hypertension
Hypertension, Resistant to Conventional Therapy
Primary: Acute Procedural Safety — 4 percentage of participants
N/A N=106 Renal Denervation in Patients With Uncontrolled Hypertension (Symplicity HTN-2)
Uncontrolled Hypertension
Primary: Office Systolic Blood Pressure Reduction — -31.7; 0.9 mmHg
N/A N=53 Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension
Hypertension
Primary: Change in Office Systolic BP — -31.1 mmHg — p=<0.0001
Phase 4 N=153 Angiotensin II Blockade for Chronic Allograft Nephropathy
Kidney Disease · Proteinuria
Primary: Doubling of Interstitium or Any ESRD — 6; 12 Participants
Phase 4 N=24 Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension
Hypertension
Primary: Renal Oxygenation Changes After Chronic Treatment With Aliskiren or Hydrochlorothiazide — 20.5; 19.5; 19.5; 20.5 1/sec
N/A N=337 SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants
N/A N=128 SPYRAL DYSTAL Renal Denervation Global Clinical Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Change in Systolic Blood Pressure (SBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) — -16.6 mmHg
Phase 4 N=79 Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
Atherosclerosis
Primary: Percent Change in Atheroma Volume (PAV) in the Thoracic Aorta of Spironolactone vs. Placebo — 0.5; 7.3 percentage change — p=0.0293
N/A N=70 Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
Atrial Fibrillation · Hypertension
Primary: Proportion of Subjects in Each Arm That Experience Safety Composite Events — 1; 3 Participants — p=0.28
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=27 Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
Microalbuminuria
Primary: Microalbuminuria Reported as Urinary Albumin:Creatinine Ratio — 256.1; 376.2 Ratio
Phase 4 N=201 LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
Hypertension
Primary: Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug — 0.28; -0.12 meters/second
Phase 4 N=128 ARIA (Atacand Renoprotection In NephropAthy Pt.)
Non-diabetic Nephropathy With Hypertension
Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g
Phase 4 N=237 Shiga Microalbuminuria Reduction Trial-2
Type 2 Diabetes Mellitus · Hypertension
Primary: Reduction in Albuminuria — -5.5; -6.7 percentage of UACR change
Phase 3 N=252 Randomized Study of Laser and Balloon Angioplasty Versus Balloon Angioplasty to Treat Peripheral In-stent Restenosis
Peripheral Arterial Disease
Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR
Phase 2 N=43 Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Cardiovascular Disease · Chronic Kidney Disease
Primary: Aortic Pulse Wave Velocity (PWV) — 9.90; 9.96; 7.62; 8.57 m/s — p=0.685
N/A N=52 Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis
Intracranial Arterial Stenosis · Intracranial Atherosclerosis · Ischemic Stroke
Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08